Citation Impact
Citing Papers
Can Patients at Elevated Risk of Stroke Treated With Anticoagulants Be Further Risk Stratified?
2007
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
2009 Standout
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage
2015 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Point-of-Care Testing
2012 Standout
Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation
2007
Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centers and anticoagulation clinics
2013 StandoutNobel
Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective
2006
Antithrombotic Therapy for Venous Thromboembolic Disease
2008 Standout
Pharmacology and Management of the Vitamin K Antagonists
2008 Standout
A Prospective, Randomized Pilot Trial of Model-Based Warfarin Dose Initiation using CYP2C9 Genotype and Clinical Data
2005
Bleeding with anticoagulation therapy – Who is at risk, and how best to identify such patients
2009
Effect of 0.9% Saline or Plasma-Lyte 148 as Crystalloid Fluid Therapy in the Intensive Care Unit on Blood Product Use and Postoperative Bleeding After Cardiac Surgery
2017
Intracerebral haemorrhage
2009 Standout
Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1
2004
A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation
2010 Standout
Warfarin Maintenance Dosing Patterns in Clinical Practice
2005
Meta-analysis of the relationship between risk perception and health behavior: The example of vaccination.
2007 Standout
VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation
2005
Polymorphism of human cytochrome P450 enzymes and its clinical impact
2009
Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma
2010
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays
2010 StandoutNobel
Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach
2009 Standout
Perioperative Management of Antithrombotic Therapy
2012 Standout
Oral Anticoagulant Therapy
2012 Standout
Antithrombotic Therapy for VTE Disease
2016 Standout
The Revised Human Liver Cytochrome P450 “Pie”: Absolute Protein Quantification of CYP4F and CYP3A Enzymes Using Targeted Quantitative Proteomics
2014
Emergency Hospitalizations for Adverse Drug Events in Older Americans
2011 Standout
Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes
2010
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
2009 Standout
Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants
2014
A Prospective Natural-History Study of Coronary Atherosclerosis
2011 Standout
Evaluation of a Novel Transfusion Algorithm Employing Point-of-care Coagulation Assays in Cardiac Surgery
2014
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
2005
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
2013 Standout
Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
2009
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
CYP2C9 Genotype-guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study
2007
Genetic and clinical factors relating to warfarin dosing
2009
Influenza vaccination in healthcare workers
2009
The Missing Diversity in Human Genetic Studies
2019 Standout
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
2011 Standout
Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo-controlled, multicenter clinical trial
2013
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
2009 Standout
Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy
2014 Standout
A new high-performance liquid chromatographic method for determination of warfarin enantiomers
2005 StandoutNobel
The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition
2016 Standout
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention
2009
The Pharmacology and Management of the Vitamin K Antagonists
2004 Standout
Common Variants of Cytochrome P450 4F2 Exhibit Altered Vitamin E-Ω-Hydroxylase Specific Activity
2010
A genome-wide association study of acenocoumarol maintenance dosage
2009
Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy
2009
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Coagulopathy and blood component transfusion in trauma
2005
Novel CYP2C9 Promoter Variants and Assessment of Their Impact on Gene Expression
2008
A Randomized Clinical Trial Investigating the Relationship Between Aprotinin and Hypercoagulabilityin Off-Pump Coronary Surgery
2009
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
2017 Standout
Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis
2008
Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records
2006 StandoutNobel
Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)
2006
CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese
2006
Mining electronic health records: towards better research applications and clinical care
2012 Standout
Genetic Determinants of Response to Warfarin during Initial Anticoagulation
2008
von Willebrand disease (VWD): evidence‐based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA) 1
2008
Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation
2005
Reduction of Fresh Frozen Plasma Requirements by Perioperative Point-of-Care Coagulation Management with Early Calculated Goal-Directed Therapy
2012
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Supramolecular biomaterials
2015 Standout
Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis
2019 Standout
Personalized Medicine: Progress and Promise
2011
Delivery of Optimized Anticoagulant Therapy: Consensus Statement from the Anticoagulation Forum
2008
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants
2014
Influence of CYP2C9 and VKORC1 on Warfarin Dose, Anticoagulation Attainment and Maintenance Among European–Americans and African–Americans
2008
Intracerebral Hemorrhage Associated With Oral Anticoagulant Therapy
2005
Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon
2008
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen
2005
Integrating Genomic-Based Clinical Decision Support Into Electronic Health Records
2010
Guidelines for the Primary Prevention of Stroke
2014 Standout
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage
2010 Standout
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model
2014
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
2009
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update
2017
Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease
2013
Implementation of an off-label recombinant factor VIIa protocol for patients with critical bleeding at an academic medical center
2014
Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study
2018 StandoutNobel
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
CYP2C9*8 is Prevalent Among African–Americans: Implications for Pharmacogenetic Dosing
2009
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial Fibrillation
2006
2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2008 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack
2010 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
First-line Therapy with Coagulation Factor Concentrates Combined with Point-of-Care Coagulation Testing Is Associated with Decreased Allogeneic Blood Transfusion in Cardiovascular Surgery
2011
CLINICAL AND TOXICOLOGICAL RELEVANCE OF CYP2C9: Drug-Drug Interactions and Pharmacogenetics
2005
Works of Charles Eby being referenced
Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin
2003
External Peer Review Quality Assurance Testing in von Willebrand Disease: The Recent Experience of the United States College of American Pathologists Proficiency Testing Program
2006
Transfusion medicine service policies for recombinant factor VIIa administration
2004
Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias
2009
A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery
2008
Performance of Commercial Platforms for Rapid Genotyping of Polymorphisms Affecting Warfarin Dose
2008
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype
2005
Use of pharmacogenetics to guide warfarin therapy
2004
Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin
2008
Improving Influenza Vaccination Rates in the Workplace
2009
Prediction and management of bleeding in cardiac surgery
2009
The Pharmacogenetics of Coumarin Therapy
2005
Novel anticoagulants and laboratory testing
2013
CYP4F2 genetic variant alters required warfarin dose
2008
Genetic-based dosing in orthopedic patients beginning warfarin therapy
2007
Hemostatic complications associated with paraproteinemias.
2003